Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: DOCS.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Doximity (DOCS) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$29

+10.6%

2031

5-Year

NEUTRAL

$47

+79.5%

Published batch insight

Healthcare Professional Network Monopolist Exploits Market Mispricing Through Aggressive Buybacks

High consensus confirms the platform's entrenched monopoly across verified United States physicians, generating 46% free cash flow margins and an 8% net buyback yield. Sharp divergence surrounds whether rising compute costs and zero-priced competitors permanently cap terminal growth or whether clinical artificial intelligence unlocks premium enterprise software monetization.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Michael Burry (Vulture), J.P. Morgan (Titan), Universal Investor (Polymath), Ray Dalio (Strategist), Machiavelli (Insider), Superintelligence (Anthropologist), Elon Musk (Visionary), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Doximity at the forecast anchor (2026-09-18): $17,947 in five years versus $13,892 for S&P 500 benchmark.

Doximity · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Doximity compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 26.11 USD1-year price return: +10.61%5-year price return: +79.47%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	26.28	+0.65%	+0.65%	Early fiscal 2027 second-quarter results confirm revenue guidance stabilization, but elevated artificial intelligence infrastructure costs and high stock-based compensation cap margin recovery. Programmatic share repurchases absorb selling pressure, establishing an initial valuation floor.
Q1 2027	27.04	+2.89%	+3.56%	Calendar 2027 pharmaceutical marketing commitments demonstrate steady baseline renewals. Cash flow generation remains strong, while persistent share retirements slightly increase per-share figures, overcoming broader technology multiple compression driven by restrictive interest rates.
Q2 2027	28.03	+3.67%	+7.36%	Full-year fiscal 2027 results reveal that research spending growth is beginning to crest. Conservative initial fiscal 2028 guidance tempers enthusiasm, though free cash flow generation exceeding $300 million reassures institutional allocators.
Q3 2027	28.88	+3.03%	+10.61%	Initial commercialization data from point-of-care clinical search sponsorships emerges. While inference overhead keeps gross margins near 85%, modest operating leverage and ongoing float retirement support a steady, measured price advance.
Q4 2027	30.25	+4.74%	+15.86%	Pharmaceutical commercial clients increase second-half digital allocations to defend branded drugs facing patent expiries. Health systems expand enterprise workflow software trials, diversifying cash flows and improving forward visibility.
Q1 2028	31.36	+3.66%	+20.10%	Fiscal 2028 concluding numbers demonstrate revenue growth stabilizing near high single digits. Cumulative share repurchases reduce diluted share counts below 180 million, mechanically compounding earnings per share across institutional holdings.
Q2 2028	32.23	+2.78%	+23.43%	Fiscal 2029 guidance reflects steady mid-single-digit expansion. The resolution of legacy securities litigation risks reduces governance discounts, allowing pristine debt-free balance sheet cash reserves to receive full valuation credit.
Q3 2028	33.28	+3.25%	+27.45%	Macroeconomic interest rate stabilization supports mid-cap healthcare software multiples. Verified prescriber active engagement metrics remain resilient above 800,000 clinicians, effectively defending core digital advertising inventory pricing against venture-funded competitors.
Q4 2028	34.53	+3.78%	+32.26%	Year-end pharmaceutical budget deployments flow heavily into verified physician digital channels as consumer television ad restrictions take effect. Record quarterly cash generation funds continuous open-market share cancellations.
Q1 2029	35.63	+3.17%	+36.46%	Annual life-sciences contract renewals show steady net retention rates. Margins stabilize as engineering productivity normalizes and unit compute costs decline, delivering a solid quarterly operating earnings expansion.
Q2 2029	36.97	+3.77%	+41.60%	Fiscal 2029 closes with annual revenue surpassing $800 million. Operating margins recover toward 36%, proving that earlier technology outlays expanded platform utility rather than causing structural operational decay.
Q3 2029	37.89	+2.47%	+45.10%	Seasonal late-summer trading brings modest valuation consolidation. Underlying cash flows compound steadily as enterprise hospital contracts for scheduling and credentialing expand across regional healthcare networks.
Q4 2029	39.20	+3.46%	+50.12%	Pharmaceutical marketing deployments accelerate across oncology and immunology pipelines. High-margin digital detailing modules convert incremental top-line gains directly into discretionary cash, sustaining disciplined capital return execution.
Q1 2030	40.14	+2.42%	+53.75%	Enterprise software subscriptions reach approximately 20% of blended corporate sales, reducing dependence on cyclical advertising. Steady float retirement continues providing mechanical EPS accretion ahead of baseline sales growth.
Q2 2030	41.15	+2.50%	+57.60%	Fiscal 2030 full-year results reflect diluted shares dropping toward 160 million. Institutional investors reclassify the platform as an enduring medical communications utility, establishing an unshakeable premium valuation baseline.
Q3 2030	42.23	+2.62%	+61.72%	Quiet summer operations highlight durable cash-flow generation. Despite presence of free clinical point tools across the industry, Doximity's encrypted messaging, dialer ubiquity, and verified network defend customer retention.
Q4 2030	43.41	+2.80%	+66.25%	Strong fourth-quarter promotional bookings and enterprise hospital software renewals deliver clean earnings execution. Unencumbered liquidity shields operations entirely from broader credit volatility and corporate borrowing pressures.
Q1 2031	44.43	+2.36%	+70.18%	Fiscal 2031 concludes with annual free cash flow crossing $420 million. Consistent capital allocation and disciplined management cement high returns on invested capital across shifting healthcare regulatory environments.
Q2 2031	45.84	+3.16%	+75.55%	Mature software economics generate predictable, high-margin cash distributions. Management signals ongoing commitment to share repurchases alongside potential regular dividend initiation, broadening institutional shareholder demand.
Q3 2031	46.86	+2.23%	+79.47%	The five-year forecast horizon closes with equity compounding driven by ownership concentration, asset-light cash conversion, and an entrenched professional monopoly operating at durable mid-single-digit secular expansion.

The base-case investment thesis identifies an asset-light medical workflow monopoly navigating an intensive technological reinvestment cycle. While headline revenue growth has decelerated to mid-single digits amid biopharma procurement caution, core platform engagement remains unmatched, capturing over 80% of verified domestic physicians. Trailing free cash flow conversion of 46% to 49% generates approximately $300 million annually, supported by zero gross funded debt. Management is aggressively utilizing this liquidity to retire roughly 8% of equity annually, mechanically compounding per-share intrinsic value. Valuation sensitivity centers on whether artificial intelligence research expenditures represent temporary growth investments or permanent defensive costs required to fend off native electronic health record competition. The primary counterargument warns that venture-subsidized clinical tools and direct-to-prescriber ad scrutiny could permanently cap net revenue retention below 110%, stranding the equity as a mature digital media broker.

Key insights

Equity compensation running near 20% of revenue partially offsets gross buybacks, meaning true per-share economic accretion compounds near 4-6% net annually.
Structural gross margin dilution from 89% toward 85% reflects permanent variable inference costs rather than transitory operational overhead.
Federal crackdowns on consumer pharmaceutical advertising will systematically redirect commercial life-sciences budgets toward compliant, audited professional physician channels.

Deep Dive

Prevailing market consensus treats the business as an ex-growth digital advertising vendor whose pandemic-era expansion has permanently stalled. The crowd anchors heavily on fiscal 2027 revenue guidance slowing to 4% to 7%, GAAP net income contraction, CFO turnover, and securities class-action litigation. Investors assume biopharmaceutical commercial budget cuts and rising AI compute expenses will permanently compress operating margins below 30%, viewing the stock as a value trap.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd materially underestimates the asset's cash-generation durability and per-share compounding power, resulting in equity underpricing. Market participants fixate on optical GAAP margin compression from deliberate research outlays while completely overlooking a 46% normalized free cash flow conversion margin and an 8% net buyback yield. Crucially, consensus fails to grasp that aggressive share retirement concentrates platform cash flows, allowing per-share owner earnings to compound at double-digit rates even during modest top-line revenue expansion.

Repricing catalyst

Consecutive earnings releases throughout fiscal 2027 demonstrating stabilized operating margins alongside initial commercial revenue from sponsored clinical search modules will catalyze repricing. The first observable trigger will be sequential net revenue retention rebounding above 112% and visible float reduction in quarterly filings by early 2027. This tangible evidence of per-share earnings acceleration will force institutional allocators to abandon the ex-growth thesis and re-rate shares toward cash-flow peer multiples.

Published consensus context

Macro regime alignment

Restrictive monetary policy with benchmark policy rates near 4.00% and 10-year Treasury yields near 5.0% acts as a valuation multiple headwind for software equities. However, a zero-debt capital structure, over $680 million in liquid reserves, and negligible physical capital intensity insulate operations from credit contraction. Rising interest rates provide accretive cash yield, turning macro liquidity tightening into a strategic capital allocation advantage.

Published consensus context

Advisor disagreement

The decisive disagreement across analyses centers on whether Doximity is an indispensable medical operating system temporarily depressed by an investment cycle, or a mature digital ad broker suffering terminal growth saturation. The bullish framework assumes elevated R&D spending will quickly normalize, allowing operating margins to rebound toward 40% as AI Search monetizes. The bearish framework counters that R&D and compute costs represent permanent defensive capital required to prevent EHR incumbents from obsoleting the platform, while heavy stock-based compensation dilutes buyback benefits. Monitoring quarterly gross margins against the 85% threshold and tracking enterprise AI subscription adoption will resolve this debate.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Aggressive share cannibalization via buybacks: Management deploys exceptional free cash flow into aggressive share repurchases, retiring $432 million of common equity in fiscal 2026 and maintaining an 8% net buyback yield. With zero funded debt and authorized buyback capacity, continuous float contraction mechanically accelerates per-share earnings growth, establishing an unyielding floor under equity valuation across the five-year horizon. Expected impact: +28%.
Entrenched physician professional network monopoly: Verified clinician membership covers over 80% of United States physicians and prescribers, creating an unassailable digital network moat. Life-sciences manufacturers have no viable alternative digital channel capable of delivering targeted, audited clinical detailing at scale. This structural chokepoint defends high gross margins and secures durable, non-cyclical marketing allocations across multi-year budgeting cycles. Expected impact: +26%.
Commercial point-of-care AI Search monetization: Integrating Pathway clinical intelligence into commercial AI Search transforms the platform from a passive medical newsfeed into an active diagnostic query marketplace. Over 800,000 active prescribers executing clinical queries allow pharmaceutical brands to bid directly on commercial prescription intent. This unlocks high-intent search budgets, lifting average revenue per prescriber as monetization matures. Expected impact: +22%.
Secular pharmaceutical digital detailing migration: Pharmaceutical commercialization continues shifting away from costly, restricted field sales forces toward precision digital detailing. Simultaneously, federal scrutiny on direct-to-consumer television advertising reallocates promotional dollars into compliant, audited physician channels. This structural reallocation insulates platform demand from broader macroeconomic advertising cuts, driving steady high-single-digit top-line expansion across blockbuster therapy launches. Expected impact: +18%.

Top frictions and headwinds

Pharmaceutical commercial marketing budget retrenchment: Legislative drug price negotiations, Medicare inflation caps, and patent cliffs force top pharmaceutical clients to scrutinize promotional return on investment. Major pharmaceutical sponsors have delayed upfront campaign commitments, compressing net revenue retention from historic peaks toward 107%. This commercial caution stretches sales cycles and caps near-term top-line revenue expansion at single-digit rates. Expected impact: -18%.
Elevated AI compute and engineering overhead: Operating margins compressed from 39.9% in fiscal 2025 to 33.3% in fiscal 2026, driven by research spending surging over 40% to $131 million. Supporting clinical search, ambient scribing, and specialized reasoning models requires ongoing cloud inference and engineering talent. These recurring variable delivery costs dilute operational leverage, preventing near-term GAAP profits from matching sales expansion. Expected impact: -15%.
Competitive encroachment by free clinical tools: Venture-funded clinical AI tools and incumbent electronic health record systems like Epic and Cerner are deploying free ambient documentation and medical search directly into clinician workflows. Multihoming among physicians threatens session dwell time and caps Doximity's pricing power on workflow tools, forcing continuous defensive research spending to preserve platform engagement and advertising impression share. Expected impact: -14%.
Macro discount rate valuation multiple compression: Sustained restrictive monetary policy, with policy rates near 4.00% and 10-year Treasury yields hovering near 5.0%, structurally compresses mid-cap technology valuation multiples. Elevated cost of capital penalizes companies experiencing growth moderation, forcing equity valuation to rely strictly on tangible cash yields and share count reduction rather than speculative future enterprise multiples. Expected impact: -11%.

Tail risks

Federal ban on digital prescriber marketing: Sweeping federal healthcare legislation or administrative rules severely restrict direct pharmaceutical detailing and digital promotional targeting to physicians by early 2028. Because marketing subscriptions generate over 80% of company revenues, capping physician promotional deductibility would paralyze Doximity's commercial engine, slashing operating income by over a third and crushing terminal valuation multiples. Probability is 22% due to aggressive life-sciences lobbying. Probability: +22%. Expected impact: -42%.
EHR vendor native workflow lockout: Dominant electronic health record monopolists restrict third-party application programming interfaces and bundle native ambient scribes and clinical messaging directly into hospital user interfaces at zero cost by 2027. If clinicians abandon standalone web portals, Doximity's daily physician engagement would drop sharply, cratering advertising impression inventory and destroying net revenue retention. Probability is 28% given vendor protectionism. Probability: +28%. Expected impact: -36%.

Tail opportunities

Enterprise clinical AI subscription breakthrough: Doximity successfully converts its Clinical AI Suite into mandatory, enterprise-wide software licenses across more than 500 major health systems by late 2028. Triggered by acute clinician burnout and institutional liability mandates, this adoption doubles health system revenue, decoupling earnings from pharmaceutical advertising cycles and lifting annual revenue growth above 20%. Probability is 32% due to sluggish hospital IT procurement. Probability: +32%. Expected impact: +42%.
Federal ban on consumer drug advertising: Federal regulatory overhaul or binding FDA rulemaking restricts direct-to-consumer television prescription drug marketing by 2028. This policy shift forces biopharmaceutical companies to reallocate billions in marketing spend into audited, compliant professional clinician channels where Doximity holds dominant market share. Such an influx would accelerate platform ad demand, expanding operating margins toward 45%. Probability is 26% due to pharmaceutical legal resistance. Probability: +26%. Expected impact: +38%.

What to monitor

Thesis watchpoints

-- Trailing twelve-month net revenue retention re-accelerating above 112% through fiscal 2027 fourth quarter confirms commercial detailing stability and pricing power.

Key insights

Quarterly GAAP gross margins falling below 84% across consecutive quarters through fiscal 2028 signals permanent inference cost erosion and margin decay.
Formal EHR vendor API restrictions or federal statutory caps on direct physician marketing by mid-2028 demands full re-underwriting of platform terminal value.

Company Financial Analysis

Doximity Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Doximity's financial performance presents a striking contrast between slowing top-line revenue and powerful cash generation. For fiscal 2026, revenue increased 13.05% to $645 million, but growth decelerated to 7.34% in the first quarter of fiscal 2027. GAAP net income contracted sharply, halving to $24.3 million in the latest quarter as spending on artificial intelligence engineering surged over 40%. However, this headline earnings drop conceals underlying cash-flow vitality. Trailing free cash flow reached $299 million, representing an elite 46% conversion margin. Operating performance reflects deliberate, front-loaded software reinvestment rather than structural business decay, providing a highly resilient foundation as commercial marketing commitments stabilize.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2026	USD 644.9M	USD 196.1M	USD 317.5M
2025	USD 570.4M	USD 223.2M	USD 266.7M
2024	USD 475.4M	USD 147.6M	USD 178.3M
2023	USD 419.1M	USD 112.8M	USD 173.4M
2022	USD 343.5M	USD 154.8M	USD 120.9M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2026	22.7x	TTM	Native	USD / USD
2025	51.8x	TTM	Native	USD / USD
2024	36.9x	TTM	Native	USD / USD
2023	57.5x	Annual	Native	USD / USD
2022	71.4x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

The company commands extraordinary pricing power, maintaining pristine gross profit margins near 89.1% in fiscal 2026. However, GAAP operating margin compressed from 39.9% in fiscal 2025 to 33.3% in fiscal 2026, and gross margins dipped toward 85% in recent quarters due to cloud inference expenses supporting clinical AI queries. This margin compression represents an intentional strategic investment rather than permanent competitive erosion. Core physician distribution carries negligible marginal delivery cost, ensuring that as enterprise software subscriptions scale and search monetization matures, operating leverage will naturally expand margins back toward mid-30% levels.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2026	USD 214.9M	33.3%	30.4%
2025	USD 227.8M	39.9%	39.1%
2024	USD 163.9M	34.5%	31.0%
2023	USD 125.1M	29.9%	26.9%
2022	USD 113.5M	33.0%	45.1%

Balance sheet and leverage

AI Review

Doximity maintains a fortress balance sheet characterized by zero funded debt, a nominal debt-to-equity ratio of 0.01, and a robust current ratio of 6.09. Liquid assets, comprising approximately $688 million in cash and marketable securities, represent the overwhelming majority of its resource base, ensuring complete operational autonomy. Stockholders' equity declined slightly in fiscal 2026 solely due to $432 million in share repurchases rather than operating losses. With zero refinancing obligations in a high-interest-rate environment, the balance sheet functions as an aggressive capital allocation tool to retire undervalued equity.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2026	USD 10.2M	USD 748.6M	USD 209M net cash	6.09x
2025	USD 12.4M	USD 915.7M	USD 197.2M net cash	6.97x
2024	USD 14.5M	USD 762.9M	USD 82.2M net cash	6.20x
2023	USD 15.6M	USD 841M	USD 142.4M net cash	6.99x
2022	USD 1.1M	USD 798.1M	USD 111.7M net cash	8.12x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Doximity operates an exceptionally capital-light business, committing just 1.39% of fiscal 2026 revenue, or roughly $9 million, to physical equipment and facilities. Because the company delivers software over existing cloud rails rather than building expensive physical data centers, capital intensity remains structurally minimal. Management directs investment through the income statement, expensing $131 million in research and development to build clinical search and documentation tools. This capital-light architecture liberates immense economic surplus, allowing the company to convert nearly all operating profit into cash that directly funds shareholder-friendly stock buybacks.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2026	USD 9M	USD 130.7M
2025	USD 6.5M	USD 93M
2024	USD 5.8M	USD 82M
2023	USD 6.2M	USD 80.2M
2022	USD 5.7M	USD 62.4M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	65	+12.1%	Not available	ORIGINAL
5Y	NEUTRAL	114	+90.3%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	24.54	26.5	27.42	14
+6M	March 18, 2027	23.56	27.31	28.78	14
+9M	June 18, 2027	23.1	28.49	31.09	14
+1Y	September 18, 2027	22.64	29.26	32.64	14
+15M	December 18, 2027	22.86	30.68	34.6	14
+18M	March 18, 2028	22.18	31.89	37.02	14
+21M	June 18, 2028	21.29	33.09	38.87	14
+2Y	September 18, 2028	21.72	34.13	40.43	14
+27M	December 18, 2028	21.93	35.49	42.85	14
+30M	March 18, 2029	21.49	36.79	45	14
+33M	June 18, 2029	21.49	38.29	46.8	14
+3Y	September 18, 2029	21.71	39.24	48.69	14
+39M	December 18, 2029	22.14	40.67	51.12	14
+42M	March 18, 2030	21.92	41.84	53.17	14
+45M	June 18, 2030	22.14	43.24	55.29	14
+4Y	September 18, 2030	22.14	44.36	58.06	14
+51M	December 18, 2030	22.58	45.7	60.38	14
+54M	March 18, 2031	22.58	46.93	62.19	14
+57M	June 18, 2031	22.81	48.56	64.68	14
+5Y	September 18, 2031	23.04	49.69	66.62	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus demonstrates that the core physician network represents an entrenched medical registry connecting over 80% of domestic prescribers, generating 45% to 49% free cash flow margins and an 8% net buyback yield. However, reports heavily correlated around the assumption that artificial intelligence expenditures are purely discretionary and will effortlessly re-accelerate revenue above 15% are downweighted. Superior independent evidence reveals that generative AI inference costs structurally sit within cost of revenues, trimming gross margins from 89% toward 85%, while stock-based compensation exceeding 20% of sales absorbs a significant portion of share repurchases. The strongest contrarian case correctly identifies that venture-subsidized clinical tools and native hospital electronic health record systems threaten to cap pricing power. Relative weights heavily reward analyses that incorporate these verified cost pressures, dilution realities, and conservative single-digit terminal revenue growth while still recognizing balance sheet resilience.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight15.0/100

Exceptional factual rigor supported by primary source evidence. Thoroughly unpacks the competitive threat of zero-priced alternatives, regulatory shifts from direct-to-consumer advertising into professional detailing, gross margin compression from inference costs, and dilution leakage from equity compensation.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight13.0/100

Exemplary analytical discipline grounded in latest SEC filings. Distinguishes unadjusted free cash flow from true owner economic yield after deducting heavy stock-based compensation. Accurately models gradual monetization of clinical search against elevated variable compute and hosting expenses.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight7.0/100

Solid analysis linking cash conversion durability and share repurchases to intrinsic valuation floors. It provides sound causal mechanics regarding artificial intelligence search monetization, though it slightly downplays persistent stock-based compensation dilution and competitive pressure from zero-cost clinical search tools.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight7.0/100

Effectively balances workflow stickiness and free cash generation against near-term top-line moderation and research overhead. The causal links connecting buyback yields and point-of-care advertising monetization are coherent, though medium-term margin recovery assumptions remain slightly optimistic.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight7.0/100

Constructs a robust macrofinancial framework evaluating sovereign discount rates, sovereign debt cycles, and life-sciences marketing shifts. It accurately contextualizes zero-debt insulation against tight monetary policy, offering disciplined expectations for multi-year cash flow compounding.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight6.0/100

Accurately details enterprise clinical artificial intelligence adoption across major health systems and programmatic advertising migration. It gives fair weight to class-action litigation risks and vendor competition, maintaining a credible path for per-share intrinsic value accretion.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight6.0/100

Provides exceptional forensic focus on owner earnings, capital expenditure discipline, and cannibalistic share repurchases. The valuation framework is economically grounded, though it underweights the risk that enterprise hospital software sales face long institutional procurement delays.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight6.0/100

Identifies compelling regulatory tailwinds, including Sunshine Act compliance and HIPAA compliance, that shield verified digital detailing from traditional sales rep retrenchment. However, it assumes rapid insurer-level prior authorization adoption that exceeds current verified deployment evidence.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight6.0/100

Delivers a sharp, necessary contrarian critique highlighting operating deleverage, media multiple de-rating, and native electronic health record competition. While overly punitive on cash-flow survivability, its warnings regarding defensive engineering spend and multiple compression warrant meaningful portfolio inclusion.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight6.0/100

Offers a clear synthesis of asset-light operating leverage, physician workflow integration, and programmatic share retirement. Its valuation baseline provides an appropriate margin of safety, although top-line re-acceleration assumptions outpace near-term pharmaceutical procurement realities.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight6.0/100

Presents strong investigative insight into prescriber engagement metrics and pharmaceutical commercialization dynamics. It appropriately integrates securities class-action litigation risks while demonstrating how normalized cash generation and share repurchases support equity value over multi-year horizons.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight5.0/100

Presents an articulate argument on physician network entrenchment and operating leverage recovery. However, the path relies on aggressive multiple expansion and tripling earnings per share, which minimizes structural pharmaceutical budget headwinds and competitive ambient documentation substitutes.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight5.0/100

Raises material concerns regarding compute cost burdens and single-digit revenue saturation. While the terminal multiple stagnation case is well-argued, it underestimates how persistent 45% free cash flow conversion and consistent float retirement protect per-share compounding.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight5.0/100

Emphasizes the durable medical utility moat and defensive fortress balance sheet. The analysis provides sound reasoning regarding gross margin resilience, but its long-term multiple expansion relies on enterprise software conversion rates that remain unproven.

Skip to references

Research Provenance

References & Context

This Doximity consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 49 deduplicated sources retained for this batch.

01Documentsec.gov
02Doximity, Inc. - Form 10-Q - FY2026sec.gov
03Doximity, Inc. - Form 8-K - FY2026sec.gov
04Doximity, Inc. - Form 8-K - FY2026sec.gov
05Doximity, Inc. - Form 8-K - FY2026sec.gov
06Doximity - Doximity Announces Fiscal 2027 First Quarter Financial Resultsinvestors.doximity.com
074As Health Earned Media (8-5-26 update) – 4As Health4ashealth.org
08Doximity Sinks 24% As AI Push Fails To Ease Growth Fears - Doximity (NYSE:DOCS) - Benzingabenzinga.com
09150 Health Systems Are Now on the Doximity Clinical AI Suiteblog.doximity.com
10CSRxP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS - CSRxPcsrxp.org
11Doximity Scribe: Your AI-Powered Medical Documentation Assistantdoximity.com
12pharmaceutical marketing - DTC Perspectivesdtcperspectives.com
13OpenEvidence vs Doximity Ask (2026): Full Comparisonevidencemd.ai
14Open Evidence AI Review 2026: Features and Alternatives | Fastiofast.io
152026 forecast: Pharma ad dollars will continue shifting away from traditional TVfiercepharma.com

And 34 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

11 fields

cash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields

Cash flow

4 fields

capitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities

annual: 2019-03-31–2026-03-31, 8 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.